The Global Microcrystalline Cellulose Market Continues To Grow Owing To the High Demand for Microcrystalline Cellulose in Several End-Use Sectors

 

Microcrystalline Cellulose

Microcrystalline Cellulose Market, by Source Type (Wood Based, Non-wood Based), By End Use Industry (Pharmaceutical, Food & Beverages, Cosmetics & Personal Care, and Others), and by Region (North America, Latin America, Asia Pacific, Europe, and Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030.

Market Overview:

Microcrystalline Cellulose is a polymer made from wood pulp and is one of the most commonly used pharmaceutical binders. It has excellent binding properties and is available in various particle sizes. As it is a natural, environmentally friendly material, it is also used in food products. For instance, it is added to foods as a bulking agent to help them stay fresher for longer. Unlike other binding agents, it does not affect the taste or texture of the food. The crystalline structure of microcrystalline cellulose is insoluble in water. This makes it an ideal binding agent for many applications. While it is commonly manufactured from wood pulp, it has also been synthesized from other sources. In fact, scientists have investigated the possibility of producing it from spruce and cotton.

Competitive Landscape:

Major players operating in the global Microcrystalline Cellulose Market include Chemfield Cellulose, RanQ, Accent Microcell Pvt. Ltd., Anhui Sunhere Pharmaceutical Excipients Co., Ltd., Maple Biotech Pvt. Ltd., Quadra Chemicals, Foodchem International Corporation, Sigachi Industries Pvt. Ltd, Avantor Inc., Dupont, Asahi Kasei Corporation, JRS Pharma, Mingtai Chemical Co., Ltd, DFE Pharma, Rayonier Advanced Materials, and Huzhou City Linghu Xinwang Chemical Co., Ltd.

Key Market Drivers:

Increasing developments by key players in the Global Microcrystalline Cellulose Market are expected to augment the growth of the market. For instance, in June 2022, Asahi Kasei Medical acquired Bionova Scientific, LLC, in order to manufacture several types of biologics such as vaccines, cytokines, and microcrystalline cellulose. Unlike other substances, cellulose is extremely resistant to reagents, making it ideal for pharmaceutical applications. There are several different processes used to create MCC. These include acid hydrolysis, steam explosion, enzyme-mediated, and reactive extrusion. Each of these processes produces a different crystalline structure. Moreover, the high usage of microcrystalline cellulose in several other end-use sectors is estimated to enhance the growth of the global microcrystalline cellulose market.

Covid-19 Impact Analysis:

During the COVID-19 pandemic, there have been several developments in the global microcrystalline cellulose market. For instance, in July 2021, DFE Pharma introduced Pharmacel sMCC 90, which is silicified microcrystalline cellulose (MCC).

Key Takeaways:

North America is expected to dominate the growth of the global Microcrystalline Cellulose Market, owing to the high prevalence of biotechnology companies in the region. For instance, according to the American Biotechnology Association, there are currently around 3,025 biotechnology businesses in the United States.

The Asia Pacific is estimated to witness high growth in the global microcrystalline cellulose market, owing to the increasing developments and expansions done by key players in the region. For instance, in January 2021 SBU, Asahi Kasei's specialty solutions announced that the company will be building a second microcrystalline cellulose production plant at its Mizushima Works in Kurashiki, Okayama, Japan.